Soliton Announces Positive Interim Clinical Trial Results with 27% Average Reduction in Scar Volume From Single Non-Invasive Treatment

Stock Information for Soliton Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Soliton Inc.

Soliton Files 510(k) with FDA for RAP Device for the Reduction of Cellulite
Soliton Announces Pricing of Public Offering
Soliton Announces Proposed Public Offering of Common Stock
Soliton Reports Positive Pivotal Cellulite Clinical Trial Results
Soliton To Announce Results of Pivotal Cellulite Clinical Trial
Soliton Announces Pivotal Cellulite Clinical Trial Results to be Presented at AAD Virtual Meeting June 12-14
Soliton Reports First Quarter 2020 Results
Soliton Announces First Quarter 2020 Financial Results and Business Update on Thursday, May 14, 2020

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.